Key takeaway
Ретатрутид (Retatrutide) — потрійний агоніст GLP-1, GIP і глюкагонових рецепторів. Phase 3 TRIUMPH-1 (topline, травень 2026) показала зниження ваги до 28.3% за 80 тижнів на дозі 12 мг, до 30.3% за 104 тижні в extension; Phase 2 (NEJM 2023) — до 24.2% за 48 тижнів. Продукт нового покоління для корекції ваги; не схвалений FDA/EMA, подача BLA у США планується у Q1 2027.
Retatrutide — Triple Agonist GLP-1/GIP/Glucagon
Triple agonist of GLP-1 + GIP + glucagon — investigational molecule (Eli Lilly). Up to -28.3% body weight over 80 weeks in Phase 3 TRIUMPH-1 (topline 2026). Not approved by FDA/EMA.
Phase 3 TRIUMPH-1, 80 weeks (topline 2026)
What is Retatrutide?
LY3437943 · Phase 3
Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP and glucagon receptors. It is the first product to simultaneously activate three key signaling pathways for weight regulation.
Unlike Ozempic (semaglutide, single receptor — GLP-1) or Mounjaro (tirzepatide, dual receptor — GLP-1 + GIP), Retatrutide adds a third component — the glucagon receptor, which increases energy expenditure and thermogenesis.
Topline Phase 3 TRIUMPH-1 results (Lilly, May 2026) confirmed record efficacy — up to 28.3% weight loss over 80 weeks at 12 mg (efficacy estimand), and up to 30.3% at 104 weeks in the extension. Phase 2 (NEJM, 2023): up to 24.2% over 48 weeks.
🔬 Key advantage: Retatrutide is the only triple agonist. Three receptors simultaneously = appetite suppression (GLP-1) + fat metabolism (GIP) + increased thermogenesis (glucagon).
How Retatrutide Works
Triple action on three receptors simultaneously — GLP-1, GIP and glucagon — delivers the highest efficacy among all weight management products.
You inject once a week (thin needle, subcutaneous — painless)
Three receptors receive the signal simultaneously: appetite decreases, fat metabolism activates, energy expenditure increases
In Phase 3 TRIUMPH-1, participants on 12 mg lost an average of up to −28.3% body weight over 80 weeks (topline 2026) — combined with healthy eating and specialist support (Retatrutide — investigational, not FDA/EMA approved)
GLP-1: Appetite Suppression
Acts on hunger centers in the hypothalamus, reducing appetite and food cravings. Slows gastric emptying for prolonged satiety. The primary mechanism of Ozempic.
GIP: Fat Metabolism
Enhances fat tissue burning and improves insulin sensitivity. This receptor is present in Mounjaro but absent in Ozempic — making the dual agonist more effective.
Glucagon: Energy Expenditure
The unique third component of Retatrutide. Increases thermogenesis and basal metabolism — the body burns more calories even at rest. Absent in Mounjaro and Ozempic.
Retatrutide acts simultaneously on three receptors: GLP-1 suppresses appetite, GIP improves fat metabolism, and glucagon boosts thermogenesis. The triple mechanism delivered up to −28.3% weight loss over 80 weeks on the 12 mg dose in Phase 3 TRIUMPH-1 (topline 2026) — more than dual (Mounjaro) or mono-agonists (Ozempic) achieved in their separate trials.
Triple Advantage of Retatrutide
Ozempic acts through 1 receptor (GLP-1). Mounjaro — through 2 receptors (GLP-1 + GIP). Retatrutide adds a third — the glucagon receptor, which triggers thermogenesis and increases basal metabolism.
The third component is a revolution: the body burns more calories even at rest. This is precisely why Retatrutide showed the highest efficacy among all GLP-1 agonists in clinical trials.
Which product is right for you?
Retatrutide, Mounjaro or Ozempic? Take the 8-step survey — and get a personalized recommendation.
Start the quiz →
Which product
is right for you?
Retatrutide, Mounjaro or Ozempic? Take the 8-step survey — and get a personalized recommendation.
No obligations. Results immediately after completion.
Who is Retatrutide For
✓Recommended
- ✓BMI ≥ 27 with a desire to lose weight
- ✓Insufficient effect from single/dual agonists
- ✓Desire for maximum efficacy
- ✓Metabolic syndrome or insulin resistance
- ✓Readiness for a long-term program
✕Not Recommended
- ✕Pregnancy and breastfeeding
- ✕Age under 18
- ✕Medullary thyroid carcinoma (MEN2)
- ✕Acute pancreatitis
- ✕Allergy to components
Not sure? Ask a DOZA specialist — free consultation.
Retatrutide Clinical Trial Results
Phase 3 TRIUMPH-1 (topline, 2026)
In the Phase 3 TRIUMPH-1 trial (NCT05929066, topline May 2026), 2,339 adults with obesity or overweight received Retatrutide 4, 9 or 12 mg or placebo over 80 weeks. At 12 mg, mean weight loss was 28.3% (efficacy estimand) vs 2.2% on placebo — the highest published result in the GLP-1 class. In the extension (BMI≥35, 532 participants) — up to 30.3% at 104 weeks. Not approved by FDA/EMA; US BLA submission planned for Q1 2027.
For comparison: Mounjaro (tirzepatide) showed -22.5% over 72 weeks (SURMOUNT-1), and Ozempic (semaglutide) — -15% over 68 weeks. Retatrutide showed the highest numeric result in the class, but this is a cross-trial comparison: a direct head-to-head trial vs tirzepatide (NCT06662383) is still ongoing, so clinical superiority has not been established.
Results by Dose (Phase 2, NEJM 2023)
- • 1 mg: -8.7% weight over 48 weeks
- • 4 mg: -17.1% weight over 48 weeks
- • 8 mg: -22.8% weight over 48 weeks
- • 12 mg: -24.2% weight over 48 weeks
Key Phase 2 Findings (NEJM 2023)
- • 100% of participants on 12 mg lost ≥5% weight
- • 93% of participants — ≥10% weight
- • 83% of participants — ≥15% weight
- • Third receptor (glucagon) increased the effect by ~10%
Retatrutide Dosing
Phase 3 TRIUMPH protocol: start at 2 mg once weekly, escalating every 4 weeks (2 → 4 → 6 → 9 → 12 mg). Trial target doses are 4, 9 and 12 mg; the optimal dose is selected by a specialist.
Starting dose for all Phase 3 TRIUMPH participants. Body adaptation, mild appetite reduction.
Primary target dose. Active weight loss, appetite and metabolism control.
Intermediate escalation steps per the TRIUMPH protocol. 9 mg is the target dose for one of the trial arms.
Highest protocol dose. In trials — up to -28.3% weight loss over 80 weeks (Phase 3 TRIUMPH-1, 12 mg, topline 2026).
Retatrutide Adaptation Features
Adaptation symptoms are similar to other GLP-1 agonists. Gradual dose escalation minimizes discomfort.
A DOZA specialist supports the entire adaptation process and helps minimize any discomfort. Consultation — via Telegram.
Choose Your Retatrutide
Individual dose or pre-filled injector pen
ALLUVI by dose
Retatrutide · from 1.5 to 12 mgIndividual ALLUVI dose
- ✓ Precise dosing tailored to you
- ✓ From 1 dose — try it
- ✓ Specialist support
Synedica Retatrutide
40 mg · 4 doses · Made in Germany⚠️ Third-party manufacturer · not Eli Lilly · investigational
15,500 ₴
- ✓ 40 mg (4 doses of 10 mg)
- ✓ Made in Germany (Leipzig)
- ✓ Verify at synedica.io/verify
Alluvi Retatrutide
40 mg · 4 doses · Pre-filled pen⚠️ Third-party manufacturer · not Eli Lilly · investigational
- ✓ 40 mg (4 doses of 10 mg)
- ✓ 1 injection per week
- ✓ Pre-filled pen — ready to use
Pen Peptide
12 mg · GoQuick pen⚠️ Third-party manufacturer · not Eli Lilly · investigational
- ✓ Dose: 12 mg
- ✓ 1 injection per week
- ✓ GoQuick — convenient format
* Prices are approximate. Contact a specialist for exact pricing and availability.
How the Retatrutide Dose is Gradually Increased
Starting with the minimum dose to adapt the body to the triple agonist. A DOZA specialist monitors the entire process.
| Dose | Weeks | Purpose |
|---|---|---|
| 2 mg | 1–4 | Adaptation |
| 4 mg | 5–8 | Initial |
| 8 mg | 9–12 | Working dose |
| 12 mg | 13+ | Maximum |
* Dosing is selected by a DOZA specialist after a free consultation
Retatrutide vs Mounjaro vs Ozempic
| Parameter | Retatrutide | Mounjaro | Ozempic |
|---|---|---|---|
| Active ingredient | Retatrutide | Tirzepatide | Semaglutide |
| Mechanism of action | ✅ GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Number of receptors | ✅ 3 (triple) | 2 (dual) | 1 (single) |
| Weight loss | ✅ -28.3% (Phase 3 TRIUMPH-1) | -22.5% (SURMOUNT-1) | -15% (STEP-1) |
| Manufacturer | Eli Lilly (molecule) / third-party manufacturers (product) | Eli Lilly | Novo Nordisk |
| Thermogenesis | ✅ ✅ Yes (glucagon) | ❌ No | ❌ No |
| Frequency | 1× per week | 1× per week | 1× per week |
Detailed comparison of Mounjaro and Ozempic — Mounjaro vs Ozempic: Full Comparison
Retatrutide Catalog
Retatrutide is available at DOZA with delivery across Ukraine. Cold chain 2–8°C, specialist consultation, program support.
📚 Sources
- • Retatrutide Phase 2 (NEJM, 2023) — Triple hormone receptor agonist for obesity, 338 participants, 48 weeks, -24.2% weight loss
- • SURMOUNT-1 (NEJM, 2022) — Tirzepatide for weight management, 2539 participants, 72 weeks, -22.5%
- • STEP-1 (NEJM, 2021) — Semaglutide 2.4 mg, 1961 participants, 68 weeks, -14.9%
- • Eli Lilly: Retatrutide Phase 3 TRIUMPH program initiated (2023)
Frequently Asked Questions about Retatrutide
Retatrutide is an innovative triple receptor agonist targeting GLP-1, GIP and glucagon. Unlike existing products (Ozempic — single receptor, Mounjaro — dual), Retatrutide activates three key weight regulation pathways simultaneously, providing triple action for weight control. Retatrutide is an investigational Phase 3 molecule (TRIUMPH program, Eli Lilly).
Valentyna Tytorenko
Diploma-certified endocrinologist, certified dietitian and nutritionist
Take a free test
In 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
Take the testTake a free test
In 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
Take the testSee Also
Retatrutide Catalog
Retatrutide with delivery across Ukraine
Mounjaro
Dual GLP-1+GIP — up to -22.5% weight loss
Ozempic
GLP-1 agonist — up to -15% weight loss
Weight Loss with DOZA
All weight loss methods and programs
Retatrutide — Complete Guide 2026
Why the triple agonist is called 'heavy artillery'
Retatrutide vs Mounjaro — What to Choose
-28.3% vs -22.5%: detailed comparison for 2026
Retatrutide Side Effects
Difference from Mounjaro and Ozempic — what to expect
Retatrutide Dosing — 2 → 12 mg
How to start without setbacks: step-by-step guide